血清Gd-IgA1分子对IgAN诊断价值的研究进展
Research Progress of the Diagnostic Value of Serum Gd-IgA1 Molecule for IgAN
DOI: 10.12677/ACM.2020.105120, PDF,   
作者: 朱敏敏：甘肃中医药大学，甘肃 兰州；马志刚*：甘肃省人民医院，甘肃 兰州
关键词: IgA肾病；血清Gd-IgA1水平；肾活检；IgA Nephropathy； Gd-IgA1 Levels； Renal Biopsy
摘要: IgA肾病(IgAN)又称Berger’s病，由J. Berger和Hinglais于1968年首次提出，它是全世界范围内最常见的原发性肾小球疾病，也是导致终末期肾脏病(ESRD)最常见的病因，亚洲是IgAN的高发区，在我国占肾活检患者的38%~58%，并呈逐年递增的趋势，目前IgAN的发病机制仍不清楚，但是大量研究表明IgAN的发病机制与Gd-IgA1分子的形成密切相关，因此通过无创的手段测定血清Gd-IgA1的水平，探索其与IgAN发病之间的联系至关重要，也将为IgAN的诊断、治疗提供新的思路，本文就IgAN发病机制与Gd-IgA1之间的关系进行阐述。
Abstract: IgA nephropathy (IgAN) is also known as Berger’s disease. Berger and Hinglais first proposed it in 1968; it is the most common primary glomerulonephritis worldwide, and Asia is a high incidence area of IgA nephropathy, accounting for 38% to 58% of renal biopsy patients in China, and it has been increasing year by year. The pathogenesis of IgAN is still unclear, but a large number of studies have shown that the pathogenesis of IgAN is closely related to the formation of Gd-IgA1 molecules. Therefore, the level of serum Gd-IgA1 is measured by non-invasive methods to explore its pathogenesis. The relationship between them is very important and will also provide new ideas for the treatment of IgAN. This article describes the relationship between the pathogenesis of IgAN and Gd-IgA1.
文章引用：朱敏敏, 马志刚. 血清Gd-IgA1分子对IgAN诊断价值的研究进展[J]. 临床医学进展, 2020, 10(5): 782-786. https://doi.org/10.12677/ACM.2020.105120

参考文献

[1] Berger, J. and Hinglais, N. (1968) Intercapillary Deposits of IgA-IgG. Joural Durologie Et De Nephrologie, 74, 694.
[2] Reily, C., Ueda, H., Huang, Z.Q., et al. (2014) Cellular Signaling and Production of Galactose-Deficient IgA1 in IgA Nephropathy, an Autoimmune Disease. Journal of Immunology Research, 2014, Article ID: 197548. [Google Scholar] [CrossRef] [PubMed]
[3] Lai, K.N., Tang, S.C.W., Schena, F.P., et al. (2016) IgA Nephropathy. Nature Reviews Disease Primers, 2016, 16001. [Google Scholar] [CrossRef] [PubMed]
[4] Xu, L., Liu, Z.-C., Guan, G.-J., et al. (2014) Cyclosporine A Combined with Medium/Low Dose Prednisone in Progressive IgA Nephropathy. Kaohsiung Journal of Medical Sciences, 30, 390-395.
[5] 张慧, 潘薇, 林佳如, 等. IgA肾病无创性诊断:异常糖基化IgA1及其相关生物标志物的研究进展[J]. 中国中西医结合肾病杂志, 2015(10): 91-93.
[6] Suzuki, H., Kiryluk, K., Novak, J., et al. (2011) The Pathophysiology of IgA Nephropathy. Journal of the American Society of Nephrology, 22, 1795-1803. [Google Scholar] [CrossRef] 
[7] Robert, T., Berthelot, L., Cambier, A., et al. (2015) Molecular Insights into the Pathogenesis of IgA Nephropathy. Trends in Molecular Medicine, 21, 762-775. [Google Scholar] [CrossRef] [PubMed]
[8] Suzuki, Y., Matsuzaki, K., Suzuki, H., et al. (2014) Serum Levels of Galactose-Deficient Immunoglobulin (Ig) A1 and Related Immune Complex Are Associated with Disease Activity of IgA Nephropathy. Clinical & Experimental Nephrology, 18, 770-777. [Google Scholar] [CrossRef] [PubMed]
[9] Gale, D.P., Molyneux, K., Wimbury, D., et al. (2017) Galactosylation of IgA1 Is Associated with Common Variation in C1GALT1. Journal of the American Society of Nephrology, 28, 2158-2166. [Google Scholar] [CrossRef] 
[10] Suzuki, H., Raska, M., Yamada, K., et al. (2014) Cytokines Alter IgA1 O-Glycosylation by Dysregulating C1GalT1 and ST6GalNAc-II Enzymes. Journal of Biological Chemistry, 289, 5330-5339. [Google Scholar] [CrossRef] 
[11] He, L., Liu, H. and Peng, Y. (2014) Immune Pathogenesis of IgA Nephropathy and Its Drugable Targets. Journal of Central South University. Medical Sciences, 39, 96-101.
[12] Suzuki, H., Yasutake, J., Makita, Y., et al. (2018) IgA Nephropathy and IgA Vasculitis with Nephritis Have a Shared Feature Involving Galactose-Deficient IgA1-Oriented Pathogenesis. Kidney International, 93, 700-705. [Google Scholar] [CrossRef] [PubMed]
[13] Coppo, R. (2017) Biomarkers and Targeted New Therapies for IgA Nephropathy. Pediatric Nephrology, 32, 725-731. [Google Scholar] [CrossRef] [PubMed]
[14] Moldoveanu, Z., Wyatt, R.J., Lee, J.Y., et al. (2007) Patients with IgA Nephropathy Have Increased Serum Galactose-Deficient IgA1 Levels. Kidney International, 71, 1148-1154. [Google Scholar] [CrossRef] [PubMed]
[15] 刘翔, 任红旗. 肠肾连接与IgA肾病[J]. 中国中西医结合肾病杂志, 2015(9): 842-844.
[16] 汪力, 综述, 王少清, 审校. 肾病的发病机制及治疗进展[J]. 医学综述, 2015(15): 2712-2714.
[17] 戴好. 半乳糖缺陷IgA1 (Gd-IgA1)在IgA肾病发病机制中的作用[D]: [博士学位论文]. 北京: 北京协和医学院, 2019.
[18] Chu, K.-H. and Chiang, B.-L. (2011) Regulatory T Cells Induced by Mucosal B Cells Alleviate Allergic Airway Hypersensitivity. American Journal of Respiratory Cell and Molecular Biology, 46, 651-659. [Google Scholar] [CrossRef] 
[19] Kiryluk, K., Li, Y., Seolari, F., et al. (2014) Discovery of New Risk Loci for IgA Nephropathy Implicates Genes Involved in Immunity against Intestinal Pathogens. Nature Genetics, 46, 1187-1196. [Google Scholar] [CrossRef] [PubMed]
[20] 宋轻雷, 刘颖, 刘乃全, 杨柳, 刘大军. 血清异常糖基化IgA1在40例IgA肾病诊断中的应用价值研究[J]. 中国实用内科杂志, 2019, 39(3): 270-273.
[21] 邹敏书, 余健, 聂国明, 等.肾病及过敏性紫癜性肾炎患儿血清半乳糖缺乏IgA1测定的临床意义[J]. 华南国防医学杂志, 2012, 26(6): 542-544, 556.
[22] 李雪英, 樊均明, 杨满, 等. IgA肾病自身免疫发病机制研究进展[J]. 中西医结合肾病杂志, 2013(12): 75-77.
[23] Moldoveanu, Z., Wyatt, R.J., Lee, J.Y., et al. (2007) Patients with IgA Nephropathy Have Increased Serum Galactose-Deficient IgA1 Levels. Kidney International, 71, 1148-1154. [Google Scholar] [CrossRef] [PubMed]
[24] Zhao, Y.F., Zhu, L., Liu, L.J., et al. (2017) Pathogenic Role of Glycan-Specific IgG Antibodies in IgA Nephropathy. BMC Nephrology, 18, 301. [Google Scholar] [CrossRef] [PubMed]
[25] Placzek William, J., Yanagawa, H., Makita, Y., et al. (2018) Serum Galactose-Deficient-IgA1 and IgG Autoantibodies Correlate in Patients with IgA Nephropathy. PLoS ONE, 13, e0190967. [Google Scholar] [CrossRef] [PubMed]

为你推荐